CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells

Manja Wobus, Reshma Rangwala, Irena Sheyn, Robert Hennigan, Brigit Coila, Elyse E. Lower, Rawia S. Yassin, Lawrence (Larry) Sherman

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Type I receptor tyrosine kinases, including the epidermal growth factor receptor (EGFR) and erbB2, have been implicated in mammary carcinoma growth and metastasis. Recent evidence suggests that type I receptor signaling may be mediated by the CD44 family of transmembrane glycoproteins that also have been implicated in mammary tumor progression. Here, the authors tested whether CD44, EGFR, and erbB2 interacted and colocalized with one another in four mammary carcinoma cell lines (MCF-7, MDA-MB-231, MDA-MB-435, and MDA-MB-436) and in cytology samples obtained from patients with metastatic breast cancer. CD44 constitutively colocalized and coimmunoprecipitated with erbB2 and EGFR in all four mammary carcinoma cell lines. CD44 also colocalized with erbB2 and EGFR in all cytology samples expressing erbB2. CD44 colocalized with EGFR in cells from only 1 of 16 erbB2-negative cytology samples. These data indicate that CD44-EGFR-erbB2 protein complexes occur in a high proportion of metastatic mammary carcinomas and suggest that CD44-type I receptor colocalization may be a novel prognostic marker for aggressive mammary cancers.

Original languageEnglish (US)
Pages (from-to)34-39
Number of pages6
JournalApplied Immunohistochemistry and Molecular Morphology
Volume10
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Breast Neoplasms
Cell Biology
Cell Line
Glycoproteins
Neoplasm Metastasis
Growth
Proteins

Keywords

  • CD44
  • Epidermal growth factor receptor
  • ErbB2
  • Mammary carcinoma

ASJC Scopus subject areas

  • Anatomy
  • Medical Laboratory Technology

Cite this

CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. / Wobus, Manja; Rangwala, Reshma; Sheyn, Irena; Hennigan, Robert; Coila, Brigit; Lower, Elyse E.; Yassin, Rawia S.; Sherman, Lawrence (Larry).

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 10, No. 1, 2002, p. 34-39.

Research output: Contribution to journalArticle

Wobus, Manja ; Rangwala, Reshma ; Sheyn, Irena ; Hennigan, Robert ; Coila, Brigit ; Lower, Elyse E. ; Yassin, Rawia S. ; Sherman, Lawrence (Larry). / CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. In: Applied Immunohistochemistry and Molecular Morphology. 2002 ; Vol. 10, No. 1. pp. 34-39.
@article{4e7b8a92cceb4b909a5f6db74320fc31,
title = "CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells",
abstract = "Type I receptor tyrosine kinases, including the epidermal growth factor receptor (EGFR) and erbB2, have been implicated in mammary carcinoma growth and metastasis. Recent evidence suggests that type I receptor signaling may be mediated by the CD44 family of transmembrane glycoproteins that also have been implicated in mammary tumor progression. Here, the authors tested whether CD44, EGFR, and erbB2 interacted and colocalized with one another in four mammary carcinoma cell lines (MCF-7, MDA-MB-231, MDA-MB-435, and MDA-MB-436) and in cytology samples obtained from patients with metastatic breast cancer. CD44 constitutively colocalized and coimmunoprecipitated with erbB2 and EGFR in all four mammary carcinoma cell lines. CD44 also colocalized with erbB2 and EGFR in all cytology samples expressing erbB2. CD44 colocalized with EGFR in cells from only 1 of 16 erbB2-negative cytology samples. These data indicate that CD44-EGFR-erbB2 protein complexes occur in a high proportion of metastatic mammary carcinomas and suggest that CD44-type I receptor colocalization may be a novel prognostic marker for aggressive mammary cancers.",
keywords = "CD44, Epidermal growth factor receptor, ErbB2, Mammary carcinoma",
author = "Manja Wobus and Reshma Rangwala and Irena Sheyn and Robert Hennigan and Brigit Coila and Lower, {Elyse E.} and Yassin, {Rawia S.} and Sherman, {Lawrence (Larry)}",
year = "2002",
doi = "10.1097/00022744-200203000-00006",
language = "English (US)",
volume = "10",
pages = "34--39",
journal = "Applied Immunohistochemistry",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells

AU - Wobus, Manja

AU - Rangwala, Reshma

AU - Sheyn, Irena

AU - Hennigan, Robert

AU - Coila, Brigit

AU - Lower, Elyse E.

AU - Yassin, Rawia S.

AU - Sherman, Lawrence (Larry)

PY - 2002

Y1 - 2002

N2 - Type I receptor tyrosine kinases, including the epidermal growth factor receptor (EGFR) and erbB2, have been implicated in mammary carcinoma growth and metastasis. Recent evidence suggests that type I receptor signaling may be mediated by the CD44 family of transmembrane glycoproteins that also have been implicated in mammary tumor progression. Here, the authors tested whether CD44, EGFR, and erbB2 interacted and colocalized with one another in four mammary carcinoma cell lines (MCF-7, MDA-MB-231, MDA-MB-435, and MDA-MB-436) and in cytology samples obtained from patients with metastatic breast cancer. CD44 constitutively colocalized and coimmunoprecipitated with erbB2 and EGFR in all four mammary carcinoma cell lines. CD44 also colocalized with erbB2 and EGFR in all cytology samples expressing erbB2. CD44 colocalized with EGFR in cells from only 1 of 16 erbB2-negative cytology samples. These data indicate that CD44-EGFR-erbB2 protein complexes occur in a high proportion of metastatic mammary carcinomas and suggest that CD44-type I receptor colocalization may be a novel prognostic marker for aggressive mammary cancers.

AB - Type I receptor tyrosine kinases, including the epidermal growth factor receptor (EGFR) and erbB2, have been implicated in mammary carcinoma growth and metastasis. Recent evidence suggests that type I receptor signaling may be mediated by the CD44 family of transmembrane glycoproteins that also have been implicated in mammary tumor progression. Here, the authors tested whether CD44, EGFR, and erbB2 interacted and colocalized with one another in four mammary carcinoma cell lines (MCF-7, MDA-MB-231, MDA-MB-435, and MDA-MB-436) and in cytology samples obtained from patients with metastatic breast cancer. CD44 constitutively colocalized and coimmunoprecipitated with erbB2 and EGFR in all four mammary carcinoma cell lines. CD44 also colocalized with erbB2 and EGFR in all cytology samples expressing erbB2. CD44 colocalized with EGFR in cells from only 1 of 16 erbB2-negative cytology samples. These data indicate that CD44-EGFR-erbB2 protein complexes occur in a high proportion of metastatic mammary carcinomas and suggest that CD44-type I receptor colocalization may be a novel prognostic marker for aggressive mammary cancers.

KW - CD44

KW - Epidermal growth factor receptor

KW - ErbB2

KW - Mammary carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0036176638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036176638&partnerID=8YFLogxK

U2 - 10.1097/00022744-200203000-00006

DO - 10.1097/00022744-200203000-00006

M3 - Article

C2 - 11893033

AN - SCOPUS:0036176638

VL - 10

SP - 34

EP - 39

JO - Applied Immunohistochemistry

JF - Applied Immunohistochemistry

SN - 1541-2016

IS - 1

ER -